DM
SPHS

Deerfield Management’s Sophiris Bio, Inc. SPHS Stock Holding History

Deerfield Management’s Portfolio SPHS Stock Details SPHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-123,585
Closed -$578K – 142
2013
Q3 		$578K Buy
+123,585
New +$570K 0.03% 108

Other funds holding SPHS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Deerfield Management's SPHS Position: Q4 2013 in Review

Deerfield Management sold out of Sophiris Bio, Inc. (SPHS) in Q4 2013, closing a stake of 123,585 shares — an estimated $578K sold.

Deerfield Management first reported a position in SPHS in Q3 2013 and held it in 1 quarter. The position peaked at $578K in Q3 2013. 22 funds tracked by Wall St. Rank hold SPHS as of Q4 2013.

  • Deerfield Management reported no remaining Sophiris Bio, Inc. position as of Q4 2013 after selling out during the quarter.
  • Deerfield Management sold 123,585 Sophiris Bio, Inc. shares in Q4 2013, an estimated $578K.
  • Deerfield Management first reported a position in Sophiris Bio, Inc. in Q3 2013 and held it in 1 quarter.
  • Deerfield Management's Sophiris Bio, Inc. position peaked at $578K in Q3 2013.
  • 22 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q4 2013.

Based on Deerfield Management's 13F filing for Q4 2013, filed 14 Feb 2014.